

C-66 Glucagon-like Peptide 1 Receptor Agonists

Moderator(s)/Facilitator(s): Mickael Khouzami, M.D.

Objective

After completion of this session, the participant will be able to:

- Formulate perioperative care plan for patients on GLP-1 receptor agonists.

Case Stem Question

A 55 years old obese male presented for laparoscopic cholecystectomy. He had a history of Hypertension and obesity with a body mass index of 36. A month earlier, he had started using a GLP-1 RA semaglutide for weight loss and had his last dose 7 days earlier. Despite fasting from solid food for more than 14 hours prior to presentation, he described feeling “full”. A bedside gastric ultrasound was done and it revealed a filled stomach. Given these results, a discussion was made between the surgeon, the anesthesiologist and the patient; a decision was made to proceed with the surgery using full stomach precautions due to the risk of regurgitation and pulmonary aspiration of gastric contents

Guiding Questions for Discussion

1. What are GLP-1 RAs?
2. Why are we seeing it more in our practice?
3. Do GLP-1 RAs lead to delayed gastric emptying?
4. What challenges do GLP1 RAs bring to our practice?
5. What methods can be used to assess gastric emptying?
6. What are the fasting guidelines for patients on GLP-1 RAs?

References

1. Alhiary R, Kesselheim AS, Gabriele S, Beall RF, Tu SS, Feldman WB. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. *JAMA*. 2023;330(7):650–657. doi:10.1001/jama.2023.13872
2. Marissa M. Weber; Trust the Gold Standard: All Glucagon-like Peptide-1 Receptor Agonists Can Delay Gastric Emptying. *Anesthesiology* 2024; 140:178–180 doi: <https://doi.org/10.1097/ALN.0000000000004752>
3. Deepu S. Ushakumari, Robert N. Sladen; ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists. *Anesthesiology* 2024; 140:346–348 doi: <https://doi.org/10.1097/ALN.0000000000004776>
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 2006; 368: 1696e705
5. Hulst AH, Polderman JAW, Siegelaar SE, van Raalte DH, DeVries JH, Preckel B, Hermanides J. Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. *Br J Anaesth*. 2021 Mar;126(3):567-571. doi: 10.1016/j.bja.2020.10.023. Epub 2020 Dec 17. PMID: 33341227.

6. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016; 375: 311e22
7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016; 375: 1834e44
8. Young CF, Moussa M, Jay H. Shubrook; Diabetic Gastroparesis: A Review. *Diabetes Spectr* 1 August 2020; 33 (3): 290–297. <https://doi.org/10.2337/ds19-0062>
9. Perlas A, Kruisselbrink R. POCUS spotlight: gastric ultrasound. *ASRA News* 2021;46. <https://doi.org/10.52211/asra110121.065>
10. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative>
11. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery>